Viatris Inc
Viatris Inc (VTRS): 33 pipeline candidates · 7 upcoming catalysts · ~11 mo cash runway · 33 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.0 months
N/A
Lead: Approved
33 candidates
7 upcoming, next in ~166d
0 buys · 1 sell (180d)
A transparent, data-derived signal for Viatris Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$18.3B
Cash
$1.8B
Quarterly Burn
$1.2B
Runway
11.0 mo
Revenue
$3.5B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (33 candidates)
| Drug | Phase |
|---|---|
| ac-076 for s.c. administration | Phase 1 |
| act-246475 | Phase 1 |
| act-334441 | Phase 1 |
| astepro | Approved |
| astepro | Approved |
| buprenorphine | Approved |
| buprenorphine | Approved |
| cenerimod | Phase 1 |
| clopidogrel | Phase 1 |
| combined oral contraceptives | Phase 1 |
Showing 10 of 33 candidates. Sign up for full pipeline.
Upcoming Catalysts (7)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,012
Total value held
$11.47B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 149,433,262 | $2.02B |
| blackrock, inc. | 84,359,804 | $1.14B |
| vanguard portfolio management llc | 53,911,237 | $728.3M |
| state street corp | 52,233,699 | $705.7M |
| dimensional fund advisors lp | 38,310,693 | $517.5M |
| geode capital management, llc | 31,846,107 | $429.5M |
| deerfield management company, l.p. | 20,206,170 | $273.0M |
| ameriprise financial inc | 20,014,966 | $270.4M |
| fmr llc | 16,588,514 | $224.1M |
| morgan stanley | 16,089,939 | $217.4M |
Showing top 10 of 1,012 institutional holders of Viatris Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Viatris Inc's pipeline?
Viatris Inc (VTRS) has 33 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Viatris Inc's lead drug candidate?
Viatris Inc's most advanced tracked candidate is ac-076 for s.c. administration (Phase 1) for Healthy Subjects.
What is Viatris Inc's next catalyst?
Viatris Inc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Eff" — expected December 1, 2026.
What is Viatris Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Viatris Inc has approximately 11.0 months of cash runway.
What is Viatris Inc's market capitalization?
Viatris Inc's market capitalization is approximately $18.3B.
Get the full picture on Viatris Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.